Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) has received 12 analyst ratings in the last three months, with an average 12-month price target of $34.58, up from the previous $30.29. Ratings range from bullish to indifferent, with recent actions including upgrades and initiations of coverage. The company's financial performance shows strong revenue growth and net margin, but challenges in ROA. ACADIA focuses on CNS disorder treatments and seeks to in-license or acquire complementary products.
January 24, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals has a positive outlook from analysts with an increased average price target and strong revenue growth. The company's focus on CNS disorders and strategic in-licensing or acquisitions may drive future growth.
The positive analyst ratings and raised price targets suggest a bullish sentiment, which could lead to short-term price appreciation. The company's strong revenue growth and net margin are likely to be viewed favorably by investors, supporting the stock's performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100